Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03673748 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03673748 · ClinicalTrials.gov record · last posted 2026-08-18

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells

Study acronym: MSV_LE
StatusRecruiting
PhasePhase 2
Started2022-12-27
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus nephritis. The objective of this study is to evaluate the efficacy of mesenchymal stem cells (MSCs) in achieving a full or partial response in the treatment of Lupus Nephritis (LN) during its induction period.

Protocol amendment history 2 changes detected by DataLookout

2026-08-19
Primary completion pushed: 2026-12 → 2027-12
2026-08-19
Completion pushed: 2027-12 → 2028-12
Trial Details
NCT Number NCT03673748
Lead Sponsor Red de Terapia Celular
Collaborators: Hospital del Rio Hortega, Hospital Clínico Universitario de Valladolid, University of Valladolid, Citospin
Conditions Lupus Nephritis, Lupus Erythematosus
Enrollment 20 participants
Start Date 2022-12-27
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-18